Addex Reports 2020 Half Year Financial Results and Provides Corporate Update

Geneva, Switzerland, August 12, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its second quarter and half year financial results for the periods ended June 30, 2020 and provided an update on corporate activities.
H1 2020 Operating Highlights: